EE200200544A - Kabergoliini kristallvorm II, meetod selle valmistamiseks ning seda sisaldav farmatseutiline kompositsioon - Google Patents

Kabergoliini kristallvorm II, meetod selle valmistamiseks ning seda sisaldav farmatseutiline kompositsioon

Info

Publication number
EE200200544A
EE200200544A EEP200200544A EEP200200544A EE200200544A EE 200200544 A EE200200544 A EE 200200544A EE P200200544 A EEP200200544 A EE P200200544A EE P200200544 A EEP200200544 A EE P200200544A EE 200200544 A EE200200544 A EE 200200544A
Authority
EE
Estonia
Prior art keywords
cabergoline
preparation
pharmaceutical composition
composition containing
crystalline form
Prior art date
Application number
EEP200200544A
Other languages
English (en)
Estonian (et)
Inventor
Tomasi Attilio
Magenes Stefania
Ramella Giuliano
Ungari Mario
Pandolfi Marco
Original Assignee
Pharmacia Italia S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia S.P.A. filed Critical Pharmacia Italia S.P.A.
Publication of EE200200544A publication Critical patent/EE200200544A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EEP200200544A 2000-03-24 2001-03-19 Kabergoliini kristallvorm II, meetod selle valmistamiseks ning seda sisaldav farmatseutiline kompositsioon EE200200544A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0007307.2A GB0007307D0 (en) 2000-03-24 2000-03-24 Crystalline form || of cabergoline
PCT/EP2001/003098 WO2001072747A1 (en) 2000-03-24 2001-03-19 Crystalline form ii of cabergoline

Publications (1)

Publication Number Publication Date
EE200200544A true EE200200544A (et) 2004-04-15

Family

ID=9888432

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200544A EE200200544A (et) 2000-03-24 2001-03-19 Kabergoliini kristallvorm II, meetod selle valmistamiseks ning seda sisaldav farmatseutiline kompositsioon

Country Status (31)

Country Link
US (2) US6673806B2 (ja)
EP (1) EP1280803B1 (ja)
JP (1) JP2003528874A (ja)
KR (1) KR20020081492A (ja)
CN (1) CN1221550C (ja)
AR (1) AR048279A1 (ja)
AT (1) ATE282038T1 (ja)
AU (1) AU783064B2 (ja)
BR (1) BR0109508A (ja)
CA (1) CA2399540A1 (ja)
CZ (1) CZ20023177A3 (ja)
DE (1) DE60107074T2 (ja)
DK (1) DK1280803T3 (ja)
EA (1) EA004376B1 (ja)
EE (1) EE200200544A (ja)
ES (1) ES2231461T3 (ja)
GB (1) GB0007307D0 (ja)
HK (1) HK1052692B (ja)
HU (1) HUP0300389A3 (ja)
IL (1) IL151670A0 (ja)
MX (1) MXPA02009284A (ja)
MY (1) MY126071A (ja)
NO (1) NO20024527D0 (ja)
NZ (1) NZ521314A (ja)
PE (1) PE20011087A1 (ja)
PL (1) PL358252A1 (ja)
PT (1) PT1280803E (ja)
SI (1) SI1280803T1 (ja)
SK (1) SK13572002A3 (ja)
WO (1) WO2001072747A1 (ja)
ZA (1) ZA200207151B (ja)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0007309D0 (en) * 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form V|| of cabergoline
GB0007308D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline
GB0007307D0 (en) * 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form || of cabergoline
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
BR0308304A (pt) * 2002-03-15 2004-12-28 Pharmacia Corp Processo para preparar forma i cristalina de cabergolina
IL155545A (en) * 2003-04-21 2009-12-24 Finetech Pharmaceutical Ltd Solvate form of cabergoline
CA2525104A1 (en) 2003-05-08 2004-11-25 Ivax Pharmaceuticals S.R.O. Polymorphs of cabergoline
GB0409785D0 (en) * 2004-04-30 2004-06-09 Resolution Chemicals Ltd Preparation of cabergoline
GB0505965D0 (en) 2005-03-23 2005-04-27 Resolution Chemicals Ltd Preparation of cabergoline
US7339060B2 (en) 2005-03-23 2008-03-04 Resolution Chemicals, Ltd. Preparation of cabergoline
EP1953157A1 (en) 2007-01-31 2008-08-06 LEK Pharmaceuticals D.D. New crystal form of cabergoline
US20130163062A1 (en) 2011-12-22 2013-06-27 Qualcomm Mems Technologies, Inc. Mechanical smart window with continuously tunable transmission

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US149067A (en) * 1874-03-31 Improvement in steam-engine valve-gears
US144516A (en) * 1873-11-11 Improvement in faucets
US187013A (en) * 1877-02-06 Improvement in ovens for gas-stoves
US4526892A (en) * 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
GB2103603B (en) * 1981-08-11 1985-04-11 Erba Farmitalia Ergoline derivatives
GB0007308D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline
GB0007307D0 (en) * 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form || of cabergoline
GB0007309D0 (en) * 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form V|| of cabergoline
GB0007376D0 (en) 2000-03-28 2000-05-17 Knoll Ag Therapeutic agents

Also Published As

Publication number Publication date
NO20024527L (no) 2002-09-20
CN1418213A (zh) 2003-05-14
DE60107074T2 (de) 2005-10-20
EA004376B1 (ru) 2004-04-29
ES2231461T3 (es) 2005-05-16
MXPA02009284A (es) 2003-03-12
US20040072855A1 (en) 2004-04-15
ATE282038T1 (de) 2004-11-15
AU4248201A (en) 2001-10-08
AU783064B2 (en) 2005-09-22
HUP0300389A2 (hu) 2003-07-28
JP2003528874A (ja) 2003-09-30
MY126071A (en) 2006-09-29
US6800635B2 (en) 2004-10-05
WO2001072747A1 (en) 2001-10-04
BR0109508A (pt) 2002-12-17
NO20024527D0 (no) 2002-09-20
EA200201017A1 (ru) 2003-02-27
HK1052692B (zh) 2006-03-03
EP1280803B1 (en) 2004-11-10
NZ521314A (en) 2004-05-28
DK1280803T3 (da) 2005-01-24
KR20020081492A (ko) 2002-10-26
SK13572002A3 (sk) 2003-04-01
ZA200207151B (en) 2003-09-05
HUP0300389A3 (en) 2004-08-30
PE20011087A1 (es) 2001-10-04
DE60107074D1 (de) 2004-12-16
PT1280803E (pt) 2005-02-28
US6673806B2 (en) 2004-01-06
GB0007307D0 (en) 2000-05-17
US20030187013A1 (en) 2003-10-02
AR048279A1 (es) 2006-04-19
IL151670A0 (en) 2003-04-10
PL358252A1 (en) 2004-08-09
EP1280803A1 (en) 2003-02-05
CA2399540A1 (en) 2001-10-04
CN1221550C (zh) 2005-10-05
HK1052692A1 (en) 2003-09-26
SI1280803T1 (en) 2005-04-30
CZ20023177A3 (cs) 2003-03-12

Similar Documents

Publication Publication Date Title
HUP0301802A3 (en) Process for producing carvedilol, crystalline carvedilol, process for producing it and pharmaceutical composition containing it
MXPA03004402A (es) Composicion mejorada de sucralosa y procedimiento para su preparacion.
EE05232B1 (et) Reguleeritud vabastamisega graanul, meetod selle valmistamiseks ning seda sisaldav mitmehikuline ravimvorm
IL156662A0 (en) Oxazolidinone derivatives, process for the preparation thereof and pharmaceutical compositions containing the same
HUP0203902A3 (en) Substituted oxazolidinones, process for their preparation and pharmaceutical compositions containing them and their use
PL396568A1 (pl) Krystaliczny bursztynian O-demetylo-wenlafaksyny, kompozycja farmaceutyczna, farmaceutyczna postać dawkowania, doustna postać dawkowania, zastosowanie oraz sposób wytwarzania krystalicznego bursztynianu O-demetylo-wenlafaksyny
HUP0301187A3 (en) Novel benzyl-piperidine-derivatives, process for their preparation and pharmaceutical compositions containing them
EE200100318A (et) Kinoliini derivaat, selle ühendi kasutamine ravimina, seda sisaldav farmatseutiline kompositsioon ning meetod ühendi ja kompositsiooni valmistamiseks
HUP0204496A3 (en) Novel piperidine compounds and pharmaceutical compositions containing the same and process for preparation the same
EE05286B1 (et) Perindopriili tert-butlamiinsoola kristalliline kamma-vorm, protsess selle valmistamiseks ning seda sisaldavad farmatseutilised kompositsioonid
HK1064671A1 (en) Process for making amlodipine maleate, the amlodipine maleate prepared, the pharmaceutical composition and the use thereof
EE200200544A (et) Kabergoliini kristallvorm II, meetod selle valmistamiseks ning seda sisaldav farmatseutiline kompositsioon
HUP0303156A3 (en) Substituted 2-phenylaminoimidazoline derivatives as ip antagonists, process for their preparation and pharmaceutical compositions containing them
EE04739B1 (et) Tienüülasolüülalkoksüetaanamiinderivaadid, nende ja nende soolade valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ning vaheühend ja selle valmistamismeetod
IL154370A0 (en) Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
PL356911A1 (en) Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same
HU0100489D0 (en) New piperidine-4-sulphonamide compounds, process for their preparation and pharmaceutical compositions containing them
EE200200601A (et) Uus stabiilne tiasolidiindiooniderivaadi kristallja meetod selle valmistamiseks
HUP0302515A3 (en) Sulfanidothienopyrimidines, process for their preparation and pharmaceutical compositions containing them
HUP0303361A3 (en) Substituted 1-aminobutan-3-ol derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0204001A3 (en) Substituted aminomethyl-phenyl-cyclohexane derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0303105A3 (en) Novel aminocyclohexane derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0202322A2 (en) A substantially crystalline form of melagatran, process for obtaining it, pharmaceutical composition containing thereof and its use
HUP0203717A3 (en) Bioavailable composition containing isotretinoin and process for its preparation
PL360090A1 (en) Novel aminotriazolone compounds, method for preparing same and pharmaceutical compositions containing same